Acyclovir NEW
| Price | $39 | $51 | $80 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2026-05-15 |
Product Details
| Product Name: Acyclovir | CAS No.: 59277-89-3 |
| Purity: 99.77% | Supply Ability: 10g |
| Release date: 2026/05/15 |
Product Introduction
Bioactivity
| Name | Acyclovir |
| Description | Acyclovir (Aciclovir) is a guanine analog and orally active antiviral agent characterized by a narrow antiviral spectrum, high selectivity, and low toxicity. Acyclovir exhibits activity against HSV-1 (IC50 = 0.85 μM), HSV-2 (IC50 = 0.86 μM), and varicella-zoster virus. Acyclovir can be used for herpesvirus treatment research. |
| Kinase Assay | Total AMPK activity is measured using the method of Dagher et al. AMPK activity is quantified in the resuspended pellet as incorporation of?32P from [γ-32P]ATP (10 GBq/mmol) into a synthetic peptide with the specific target sequence for AMPK, the SAMS peptide. Radioactivity is measured using a liquid scintillation counter. Protein content in the solution containing the resupended (NH4)2SO4 pellet is determined using the Bradford method. |
| In vitro | Methods: Flow cytometry was used to analyze the cell cycle distribution of Jurkat cells treated with 10 and 100 μM acyclovir at 24, 48, and 72 hours. Results: Acyclovir induced S-phase arrest in Jurkat cells, and the sub-G1 apoptotic peak was significantly elevated at 72 hours. [4] Methods: Cell viability of Jurkat, U937, and K562 leukemia cells treated with 3–100 μM acyclovir for 24, 48, and 72 hours was assessed using the trypan blue staining Methods. Results: Acyclovir inhibited Jurkat cell viability in a dose- and time-dependent manner, while its inhibitory effect on U937 and K562 cells was weaker. [4] |
| In vivo | Methods: Female Danish Landrace pigs (n=6, weight 37–48 kg) received a single intravenous bolus injection of Acyclovir (10 mg/kg). Monitoring was conducted for 8 hours post-administration, with sampling every 30 minutes. Results: Plasma drug concentrations peaked rapidly, but CNS distribution was slow and limited. [1] Methods: Four healthy Asian elephant calves received a single intravenous bolus of Acyclovir (15 mg/kg). Blood samples were collected pre-dose and at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 12, 24, 36, and 48 h post-administration. Plasma drug concentrations were measured by LC-MS/MS. Results: At 12 h post-administration, plasma concentrations remained above the IC50 for HSV-1/2 and EHV-1. [2] Methods: Male Sprague-Dawley rats received epidural Acyclovir (0.3 mg, 0.6 mg, 0.9 mg) (dissolved in 100 μL) or intravenous Acyclovir (3 mg, 6 mg, 9 mg) (dissolved in 2 mL saline). Blood and cerebrospinal fluid (CSF) samples were collected 1 hour post-administration. Results: CSF concentrations in the epidural group were significantly higher than those in the IV group (P<0.05), while plasma concentrations were significantly lower than those in the IV group (P<0.05).[3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (8.88 mM), Sonication is recommended. DMSO : 42.92 mg/mL (190.59 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | triphosphate | thymidine | RNASynthesis | RNA Synthesis | polymerase | kinase | Inhibitor | inhibit | immunosuppression | HSV | Herpes simplex virus | DNASynthesis | DNA synthesis | DNA | Bacterial | Apoptosis | anti-herpetic | antibody | Antibiotic | Acyclovir |
| Inhibitors Related | Neomycin sulfate | Aceglutamide | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Sulfamethoxazole sodium | Terbinafine hydrochloride | Formamide | Thymidine | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate |
| Related Compound Libraries | Bioactive Compound Library | Pediatric Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Human Metabolite Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $39.00/25mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-15 | |
| $0.00/1kg |
VIP1Y
|
Hefei Lbao Physical & Chemical Science Co.,Ltd
|
2025-11-25 | |
| $0.00/25kg |
VIP5Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2025-09-29 | |
| $0.00/1kg |
VIP2Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2025-05-07 | |
| $/ |
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $150.00/1kg |
Hebei Zhuanglai Chemical Trading Co Ltd
|
2024-12-03 | ||
| $10.00/1kg |
Hebei Chuanghai Biotechnology Co., Ltd
|
2024-11-13 | ||
| $0.00/25KG |
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2024-11-13 | |
| $100.00/50kg |
VIP2Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2024-08-13 | |
| $0.00/1g |
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-08-09 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY